Mineralys Therapeutics, Inc. (MLYS) Stock Analysis

Mineralys Therapeutics (MLYS) is a clinical-stage biotech focused on solving a major unmet need in cardiovascular and renal medicine: uncontrolled and treatment-resistant hypertension. The company’s valuation is effectively a direct function of its lead—and largely sole—asset, lorundrostat, an oral, highly selective aldosterone synthase inhibitor intended to suppress aldosterone production at the source (CYP11B2) rather than blocking receptors like legacy mineralocorticoid receptor antagonists. This mechanistic distinction is positioned to deliver meaningful blood pressure control while reducing limiting off-target effects seen with older therapies (e.g., hormonal side effects and hyperkalemia-related usability constraints), aided by a claimed 374-fold selectivity that mitigates cortisol pathway risk—a historic stumbling block for the class due to CYP11B2/CYP11B1 similarity. Operationally, Mineralys is well capitalized for the pivotal stretch: it ended 2025 with ~$656.6M in cash and investments, expected to fund operations into 2028 and support a commercial launch. The key value inflection is regulatory: the FDA accepted the NDA in early 2026 and set a PDUFA target action date of Dec 22, 2026. Commercial strategy targets ~60,000 high-volume U.S. prescribers across primary care and specialists, aiming to penetrate a large end-market: ~120M U.S. adults with hypertension, with ~20M uncontrolled/resistant patients representing the initial wedge. Prescribers may prefer lorundrostat based on demonstrated 24-hour control, strong efficacy across high-risk subgroups (high BMI, CKD), and a differentiated safety/biology narrative. The primary competitive benchmark is AstraZeneca’s baxdrostat, which may reach market first and has significant scale advantages, setting up a duopoly-like contest where label breadth, safety perception, and payer access will determine long-term share.